retatrutide triple hormone receptor agonist metabolic obesity Triple–Hormone-Receptor Agonist Retatrutide for — A Phase 2 Trial # What Is Retatrutide (RETA)? The – Retatrutide helps with weight loss

after seven years

It is supplied to the laboratory market as a research-use-only reference compound

Last updated: December 15, 2025 Dr

Therapeutic Research Protocol Dose: 0.3 0.5 mg (= 610 clicks) Duration: 12 weeks Frequency: 2 3 daily, spaced 4 6 hours apart Cycle Interval: 4 6 weeks off before repeating Goal / Description: Higher-amplitude GH and IGF-1 elevation in regenerative and metabolic models

In turn, villous atrophy can impair nutrient absorption and is one of the primary mechanisms underpinning extensive nutritional deficiencies found in Celiac and inflammatory bowel diseases (198)

Systematic review registration: identifier CRD42022323788